1. |
Smith JP, Solomon TE. Effects of gastrin, proglumide, and somatostatin on growth of human colon cancer. Gastroenterology, 1988; 95(6)∶1541.
|
2. |
Pinski J, Halmos G, Yano T, et al. Inhibition of growth of MKN45 human gastriccarcinoma xenografts in nude mice by treatment with bombesin/gastrinreleasingpeptide antagonist (RC3095) and somatostatin analogue RC160. Int J Cancer, 1994; 57(4)∶574.
|
3. |
Smith JP, Doll D, Croitoru R, et al. Octreoride has no effect on advanced colon cancer. J Clin Gastroenterol, 1994; 18(3)∶245.
|
4. |
Qin Y, Cauteren MV, Osteaux M, et al. Inhibitory effect of somatostatin analogue RC160 on the growth of hepatic metastases of colon cancer in rats: a study with magnetic resonance imaging. Cancer Res, 1992; 52(21)∶6025.
|
5. |
Reubi JC, Horisberger U, Laissue J. High density of somatostatin receptors in veins surrounding human cancer tissue: role in tumerhost interaction? Int J Cancer, 1994; 56(5)∶681.
|
6. |
Reubi JC, Mazzucchelli L, Hennig I, et al. Local upregulation of neuropeptide receptors in host blood vessels around human colorectal cancer. Gastroenterology, 1996; 110(6)∶1719.
|
7. |
Davies N, Cooke TG, Jenkins SA. Therapeutic potential of octreotide in the treatment of liver metastases. Anti Cancer Drugs, 1996; 7(Suppl 1)∶23.
|
8. |
Buscail L, Delesque N, Esteve JP, et al. Stimulation of tyrosine phosphatase and inhibition of cell proliferation by somatostatin analogues: mediation by human somatostatin receptor subtypes SSTR1 and SSTR2. Proc Natl Acad Sci USA, 1994; 91(6)∶2315.
|
9. |
Buscail L, Esteve JP, SaintLaurent N, et al. Inhibition of cell proliferation by the somatostatin analogue RC160 is mediated by somstostatin receptor subtypes SSTR2 and SSTR5 through different mechanisms. Proc Natl Acad Sci USA, 1995; 92(5)∶1580.
|
10. |
Iftikhar SY, Thomas WM, Rooney PS, et al. Somatostatin receptors in human colorectal cancer. Eur J Surg Oncol, 1992; 18(1)∶27.
|
11. |
Miller GV, Farmery SM, Woodhouse LF, et al. Somatostatin binding in normal and malignant human gastrointestinal mucosa. Br J Cancer, 1992; 66(2)∶391.
|
12. |
Radulovic SS, Milovanovic SR, Cai RZ, et al. The binding of bombesin and somatostatin and their analogues to human colon cancers. Proc Soc Exp Biol Med, 1992; 200(3)∶394.
|
13. |
Miller GV, Preston SR, Woodhouse LF, et al. Somatostatin binding in human gastrointestinal tissues: effect of cations and somatostatin analogues. Gut, 1993; 34(10)∶1351.
|
14. |
Buscail L, SaintLaurent N, Chastre E, et al. Loss of sst2 somatostatin receptor gene expression in human pancreatic and colorectal cancer. Cancer Res, 1996; 56(8)∶1823.
|
15. |
Laws SA, Gough AC, Evans AA, et al. Somatostatin receptor subtype mRNA expression in human colorectal cancer and normal colonic mucosae. Br J Cancer, 1997; 75(3)∶360.
|
16. |
Goldberg RM, Moertel CG, Wieand HS, et al. A ghase Ⅲ evaluation of a somatotatin analogue (Octreotide) in the treatment of patients with asymptomatic advanced colon carcinoma. Cancer, 1995; 76(6)∶961.
|
17. |
Stewart GJ, Connor JL, Lawson JA, et al. Octreotide reduces the kinetic index, proliferating cell nuclear antigenmaximum proliferative index, in patients with colorectal cancer. Cancer, 1995; 76(4)∶572.
|
18. |
Woltering EA, Watson JC, AlperinLea RC, et al. Somatostatin analogues: angiogenesis inhibitors with novel mechanisms of action. Invest New Drugs, 1997; 15(1)∶77.
|